Abstract
We have assesed the pharmacokinetic and pharmacodynamic interaction between fluvoxamine, a serotonin reuptake inhibitor, and alprazolam, a triazolobenzodiazepine.
Healthy men took fluvoxamine maleate daily for 10 days (50 mg on days 1–3, 100 mg on days 4–10) (n=20), 1 mg of alprazolam four times daily for four days (days 7–10 of the study period) (n=20), or a combination of the two (n=20), according to a parallel study design. Alprazolam and fluvoxamine concentrations were measured in serial plasma samples by HPLC and gas chromatography respectively, and psychomotor performance and memory were assessed on days 1, 7, and 10.
Fluvoxamine increased plasma alprazolam concentrations by 100%. The mean apparent half-life of alprazolam was increased from 20 h to 34 h after fluvoxamine co-administration.
The increased plasma concentrations of alprazolam resulted in significantly greater reductions in psychomotor performance evident on day 10. Mean fluvoxamine plasma concentrations were about 25% lower in those who took the combination than in those who took only fluvoxamine; this was more likely due to heterogeneity between the treatment groups than to an effect of alprazolam.
The dosage of alprazolam should be reduced during co-administration with fluvoxamine.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Benfield P, Ward A (1986) Fluvoxamine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 32: 313–34
Van Harten J (1993) Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Clin Pharmacokinet 24: 203–220
Aden GC, Thien SG (1980) Alprazolam compared to diazepam and placebo in the treatment of anxiety disorder. J Clin Psychiatry 41: 245–248
Chouinard G, Annable L, Fountaine R, Solyom L (1982) Alprazolam in the treatment of generalized anxiety and panic disorders: a double blind placebo controlled study. Psychopharmacology 77: 229–233
Sheehan DV, Coleman JH, Greenblatt DJ, Jones KJ, Levine PH, Orsulak PJ, Peterson M, Schildkraut JJ, Uzogara E, Watkins D (1984) Some biochemical correlates of panic attacks with agoraphobia and their response to a new treatment. J Clin Psychopharmacol 4: 66–75
Smith RB, Kroboth PD (1987) Influence of dosing regimen on alprazolam and metabolite serum concentrations and tolerance to sedative and psychomotor effects. Psychopharmacology 93: 105–112
Hurst HE, Jones DR, Jarboe CH, deBree H (1981) Determination of clovoxamine concentration in human plasma by electron capture gas chromatography. Clin Chem 27: 1210–1212
Gibaldi M, Perrier D (1982) Pharmacokinetics, 2nd edn. Dekker, New York
de Vries MF, Raghoebar M, Mathlener IS, van Harten J (1992) Single and multiple oral dose fluvoxamine kinetics in young and elderly subjects. Ther Drug Monit 14: 493–498
SAS Institute, Inc. (1985) SAS User's Guide: Statistics, Version 5 Edition. SAS Institute, Inc., Cary, SC
Letz R, Baker EL (1988) NES2 Users Manual, version 4.1. Neurobehavioral Systems, Inc., Winchester, MA
Smith RB, Kroboth PD, Vanderlugt JT, Phillips JP, Juhl RP (1984) Pharmacokinetics and pharmacodynamics of alprazolam after IV and oral administration. Psychopharmacology 84: 452–456
Greenblatt DJ, Wright CE (1993) Clinical pharmacokinetics of alprazolam, therapeutic implications. Clin Pharmacokinet 24: 453–471
Brøsen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S (1993) Fluvoxamine is a potent inhibitor of cytochrome P4501 A2. Biochem Pharmacol 45: 1211–1214
Smith RB, Gwilt PR, Wright CE (1983) Single- and multiple-dose pharmacokinetics of oral alprazolam in healthy smoking and nonsmoking men. Clinical Pharmacy 2: 139–143
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fleishaker, J.C., Hulst, L.K. A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine. Eur J Clin Pharmacol 46, 35–39 (1994). https://doi.org/10.1007/BF00195913
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00195913